BioPharma Dive – AI / Data

Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study results

Published

on

The partners said the shot produced “clinically meaningful” efficacy despite missing its main study objective, a finding they blamed on a lower-than-expected rate of infections during the trial. 

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version